GAS Immunogenic Composition with Polysaccharide-Protein Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Group A Streptococcus (GAS) are inadequate due to challenges posed by its invariant capsule and highly polymorphic M proteins, leading to autoimmune responses and limited protection against globally circulating serotypes.
Innovation Solution
An immunogenic composition comprising two or more GAS polypeptide antigens, such as C5a peptidase and streptolysin O, combined with a polypeptide-polysaccharide conjugate that lacks an immunodominant N-acetyl Glucosamine side chain, utilizing non-natural amino acids for enhanced immunogenicity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional GAS vaccines targeting M proteins are used, then immune response is generated, but autoimmune responses occur and protection is limited to specific serotypes
Solution Approach 1:
The vaccine divides the GAS pathogen into multiple distinct antigenic components (M protein peptides from different serotypes, C5a peptidase, streptolysin O, and polysaccharide capsules) rather than using whole M proteins. This segmentation allows targeting of multiple serotypes simultaneously while avoiding the autoimmune triggers associated with complete M protein structures.
Solution Approach 2:
The vaccine employs a composite antigen formulation combining proteinaceous antigens (M protein peptides, C5a peptidase, streptolysin O) with polysaccharide antigens (capsular polysaccharides from different serotypes). This composite approach creates broad-spectrum immunity against multiple GAS serotypes while the polysaccharide component lacks the immunodominant GlcNAc side chain to reduce cross-reactivity with human tissues.
2Adaptability or versatility
If vaccines target invariant capsule, then broad protection is achieved, but the capsule is immunologically inert and poorly immunogenic
Solution Approach 1:
The vaccine merges the invariant polysaccharide capsule antigen with highly immunogenic protein carriers (C5a peptidase and streptolysin O). The polysaccharide capsule provides broad serotype coverage while the protein carriers supply the necessary immunogenicity to elicit strong immune responses. This combination overcomes the immunological inertness of the capsule alone.
Solution Approach 2:
The protein antigens (C5a peptidase and streptolysin O) act as intermediaries that bridge the immunologically inert polysaccharide capsule to the immune system. These proteins are highly immunogenic and facilitate the generation of immune responses against the capsule polysaccharide, enabling broad protection without relying on the poor immunogenicity of the capsule alone.
3Reliability
If M proteins are used as vaccine antigens, then immune response is generated, but high polymorphism limits protection against globally circulating serotypes
Solution Approach 1:
The vaccine uses conserved antigenic components (C5a peptidase, streptolysin O, and polysaccharide capsule structures) that are universally present across multiple GAS serotypes rather than serotype-specific M protein variants. This universal approach enables a single vaccine formulation to provide protection against globally circulating serotypes while maintaining reliable immune response generation.
Data Source
AI summary
The present disclosure provides immunogenic compositions comprising Group A Streptococcus (GAS) polypeptide antigens and at least one polypeptide-polysaccharide conjugate. The present disclosure further provides methods of using such compositions to induce immune responses against GAS infections in subjects.